NEW YORK, July 8, 2022 – PRESS RELEASE – Columbia Care Inc., one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced that at the special meeting of shareholders of the company, held July 8, 2022, the proposed business combination with Cresco Labs Inc. was approved.

RELATED: Cresco Labs Targets $2B Acquisition of Columbia Care

The shareholders voted in favor of a special resolution to approve the previously announced plan of arrangement under the Business Corporations Act (British Columbia) whereby, among other things, Cresco Labs will acquire all of the issued and outstanding shares of the company, all as more particularly described in detail in the company’s definitive proxy statement and information circular dated June 6, 2022, filed on SEDAR and with the U.S. Securities and Exchange Commission (SEC).

Voting results are as follows:

 FORAGAINSTABSTAINPercentage of shares(1) that were voted98.55%1.41%0.04%

(1) Assuming conversion of all proportionate voting shares into common shares.

At the meeting, a total of 169,938,646 Columbia Care shares were represented in person or by proxy, representing 42.6% of the Columbia Care shares issued and outstanding as of the close of business on May 10, 2022, and entitled to vote at the meeting as of the record date.

“We are grateful for the overwhelming support of our shareholders as we move forward with the combination with Cresco Labs that will reshape the industry and redefine leadership in cannabis,” Columbia Care CEO and co-founder Nicholas Vita said. “As we celebrate this milestone, we remain steadfast in executing our strategic objectives through the close of the transaction, which we anticipate will be near the end of this year.”

Full details are contained in the report of coting results for the meeting, which has been filed on SEDAR at